SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

20 November 2008

 

 

PROTHERICS PLC

(Translation of Registrant’s Name Into English)

 

 

The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F       X              Form 40-F               

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):             

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):             

 

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant
            to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes                     No          X     

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-              .

 

 

The Registrant is furnishing a copy of its announcements as reported to the Company Announcements Office of the London Stock Exchange.

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

       

 

PROTHERICS PLC

       

Date: 20 November 2008

 

By:

 

/s/ Rolf Soderstrom

       

Rolf Soderstrom

       

Finance Director





Protherics PLC


 Notification of Major Interest in Shares



London, UK; Brentwood, TN, US; 20 November 2008 -  Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, announces that, on 19 November 2008, the following notification of interest in the ordinary share capital of the Company was received from Aviva plc.



1. Reason for the notification        (please tick the appropriate box or boxes)



 

A disposal voting rights  

     X  

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached



An event changing the breakdown of voting rights



Other (please specify): 


2. Full name of person(s) subject to the notification obligation:

Aviva plc & its subsidiaries 
 

3. Full name of shareholder(s) (if different from 2.):

Registered Holder:


BNY Norwich Union Nominees Limited     
  5,959,368*

Chase GA Group Nominees Limited  
19,321,240*

Chase Nominees Limited
879,543*

CUIM Nominee Limited
4,366,418*

Vidacos Nominees Limited
65,125*

*denotes direct interest  

BNP Paribas - London
636,429

Chase Nominees Limited 
3,065,451

State Street Nominees Limited  
9,428,137

Vidacos Nominees Limited 
1,603,080    


4. Date of the transaction (and date on which the threshold is crossed or reached if different):

18 November 2008

5. Date on which issuer notified:

19 November 2008

6. Threshold(s) that is/are crossed or reached:

13% to 12% Change at Combined Interest level   


7. Notified details:






A: Voting rights attached to shares

Class/type of shares 

if possible using the ISIN CODE

Situation previous to the Triggering transaction 

           Resulting situation after the triggering transaction

Number of Shares 

Number of Voting Rights 

     Number of shares 

       Number of voting rights

           % of voting rights  

     Direct

      Direct  

Indirect 

           Direct

     Indirect


Ordinary Shares


GB0007029209

 

   

45,971,166



 

45,971,166

   


   

30,591,694

 

   

      30,591,694

   



14,733,097

 

   

          8.73%

   

 

      4.20%





B: Financial Instruments

Resulting situation after the triggering transaction 

Type of financial instrument 

          Expiration date 

   Exercise/ Conversion Period/ Date  

           Number of voting rights that may be acquired if the instrument is exercised/ converted. 

      % of voting rights



N/A








Total (A+B)

Number of voting rights                   

% of voting rights

   

45,324,791

   

12.93%





8. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable :


The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-


Aviva Investors Global Services Limited:

  • Aviva plc (Parent Company)

  • Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

  • Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

  • Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)





Proxy Voting:

9. Name of the proxy holder:

   See Section 3

10. Number of voting rights proxy holder will cease to hold:

   

11. Date on which proxy holder will cease to hold voting rights:

   




12. Additional information:

Figures are based on a revised total number of voting rights of 350,427,481






| Ends |



For further information please contact:


Protherics 


Nick Staples, Director of Corporate Affairs

+44 (0) 7919 480510  

Julie Vickers, Company Secretary 

+44 (0)1928 518010



Financial Dynamics  - press enquiries


London: Ben Atwell, Lara Mott

+44 (0) 20 7831 3113 

New York: John Capodanno

+1 212 850 5600




Or visit   www.protherics.com

 

 

 

Protherics (NASDAQ:PTIL)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Protherics Charts.
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Protherics Charts.